US Cancer Drug Soars 6%, Adding $1.7 Billion in Just One Day

Incyte Corporation (NASDAQ: INCY) surged 6.25% on March 31, closing at $95.98 on the Nasdaq. Trading volume reached about 1.55 million shares, driving its market capitalization up to roughly $19.1 billion (around ₩26 trillion), with an intraday gain of approximately $1.27 billion (about ₩1.7 trillion). This marked an unusually strong single-session rally amid a broader market pullback since the start of the year.

Analyst sentiment is mixed. Over the past week, Barclays reiterated its overweight rating on Incyte with a $117 price target, and H.C. Wainwright maintained its buy rating with a $135 target. By contrast, UBS lowered its target to $94 and kept a neutral stance. Near-term catalysts include data presentations on Incyte’s inflammation and autoimmune pipeline at the American Academy of Dermatology’s annual meeting in Denver, European Union approval of its immuno-oncology agent Geniz as a first-line treatment for anal squamous cell carcinoma, and anticipated Phase III results for tafasitamab combination therapy in diffuse large B-cell lymphoma in early April.

Headquartered in Wilmington, Delaware, Incyte is a specialty pharma company focused on oncology and inflammatory/autoimmune diseases. Its key products include Jakafi, for myelofibrosis and polycythemia vera, and Opzelura, a topical therapy for atopic dermatitis and vitiligo. As an S&P 500 constituent with substantial exposure to index funds and hedge funds, Incyte is also undergoing governance restructuring, including executive title revisions and board reconfiguration.